Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RPL701
- Development stage
- Preclinical
- Lead developer
- Riverside Pharmacueticals
- Modality
- Small Molecules
01
Overview
RPL701 is a repurposed small molecule drug candidate being developed by Riverside Pharmaceuticals for the treatment of respiratory disorders, including asthma and chronic obstructive pulmonary disease (COPD). It is a formerly clinical-stage compound that demonstrated a favorable safety profile in earlier clinical trials but was discontinued by its original sponsor due to a lack of efficacy in its initial indication. Riverside Pharmaceuticals is currently repurposing the compound for respiratory diseases based on its action on a novel, undisclosed molecular target. The program is currently in the preclinical stage of development.
Beyond the preview
Go deeper on RPL701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RPL701.